Mark F van Delft
Overview
Explore the profile of Mark F van Delft including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
3017
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
van Delft M, Chappaz S, Khakham Y, Bui C, Debrincat M, Lowes K, et al.
Nat Chem Biol
. 2019 Oct;
15(11):1057-1066.
PMID: 31591564
Activating the intrinsic apoptosis pathway with small molecules is now a clinically validated approach to cancer therapy. In contrast, blocking apoptosis to prevent the death of healthy cells in disease...
12.
Chin H, Li M, Tan I, Ninnis R, Reljic B, Scicluna K, et al.
Nat Commun
. 2018 Nov;
9(1):4976.
PMID: 30478310
Intrinsic apoptosis is critical to prevent tumor formation and is engaged by many anti-cancer agents to eliminate tumor cells. BAX and BAK, the two essential mediators of apoptosis, are thought...
13.
McArthur K, Whitehead L, Heddleston J, Li L, Padman B, Oorschot V, et al.
Science
. 2018 Feb;
359(6378).
PMID: 29472455
Mitochondrial apoptosis is mediated by BAK and BAX, two proteins that induce mitochondrial outer membrane permeabilization, leading to cytochrome c release and activation of apoptotic caspases. In the absence of...
14.
Kim E, Anko M, Flensberg C, Majewski I, Geng F, Firas J, et al.
Stem Cell Reports
. 2018 Jan;
10(2):331-338.
PMID: 29358089
Despite intensive efforts to optimize the process, reprogramming differentiated cells to induced pluripotent stem cells (iPSCs) remains inefficient. The most common combination of transcription factors employed comprises OCT4, KLF4, SOX2,...
15.
Brouwer J, Lan P, Cowan A, Bernardini J, Birkinshaw R, van Delft M, et al.
Mol Cell
. 2017 Nov;
68(4):659-672.e9.
PMID: 29149594
Certain BH3-only proteins transiently bind and activate Bak and Bax, initiating their oligomerization and the permeabilization of the mitochondrial outer membrane, a pivotal step in the mitochondrial pathway to apoptosis....
16.
Zipin-Roitman A, Aqaqe N, Yassin M, Biechonski S, Amar M, van Delft M, et al.
Oncotarget
. 2017 Feb;
8(10):16712-16727.
PMID: 28187429
The molecular determinants governing escape of Acute Myeloid Leukemia (AML) cells from DNA damaging therapy remain poorly defined and account for therapy failures. To isolate genes responsible for leukemia cells...
17.
White M, McArthur K, Metcalf D, Lane R, Cambier J, Herold M, et al.
Cell
. 2014 Dec;
159(7):1549-62.
PMID: 25525874
Activated caspases are a hallmark of apoptosis induced by the intrinsic pathway, but they are dispensable for cell death and the apoptotic clearance of cells in vivo. This has led...
18.
Okamoto T, Coultas L, Metcalf D, van Delft M, Glaser S, Takiguchi M, et al.
Proc Natl Acad Sci U S A
. 2013 Dec;
111(1):261-6.
PMID: 24363325
The B-cell CLL/lymphoma 2 (Bcl2) relative Myeloid cell leukemia sequence 1 (Mcl1) is essential for cell survival during development and for tissue homeostasis throughout life. Unlike Bcl2, Mcl1 turns over...
19.
Sleebs B, Kersten W, Kulasegaram S, Nikolakopoulos G, Hatzis E, Moss R, et al.
J Med Chem
. 2013 Jun;
56(13):5514-40.
PMID: 23767404
Developing potent molecules that inhibit Bcl-2 family mediated apoptosis affords opportunities to treat cancers via reactivation of the cell death machinery. We describe the hit-to-lead development of selective Bcl-XL inhibitors...
20.
Zhang J, Czabotar P, Policheni A, Caminschi I, Wan S, Kitsoulis S, et al.
Immunity
. 2012 Apr;
36(4):646-57.
PMID: 22483802
The immune system must distinguish viable cells from cells damaged by physical and infective processes. The damaged cell-recognition molecule Clec9A is expressed on the surface of the mouse and human...